Primary Microcephaly CRISPR Cell Models for Drug Discovery

Primary microcephaly (MCPH) is a neurodevelopmental disorder characterized by a significantly reduced head circumference (occipitofrontal circumference >2 standard deviations below the mean for age and sex) at birth, with associated intellectual disability. The global incidence is estimated at 1 in 30,000 to 1 in 250,000 live births, with higher prevalence in consanguineous populations (WHO, 2023). The condition is genetically heterogeneous, with over 25 known MCPH genes. Clinical impact includes lifelong cognitive impairment, motor delays, and in severe cases, seizures. There are no approved disease-modifying therapies, highlighting the urgent need for mechanistic research and drug discovery.

MCPH is an ideal model for studying neurogenesis, cell cycle regulation, and centrosome biology. The disease is primarily caused by defects in genes involved in centrosome function and mitotic spindle orientation, leading to reduced neuronal progenitor cell proliferation. Key research questions include: How do specific mutations disrupt neurogenesis? Can we identify therapeutic targets to enhance progenitor cell survival? Public datasets from NCBI Gene and ClinVar provide extensive mutation data, while patient-derived cell lines and iPSC models are increasingly available. Gene-edited cell models offer a powerful platform to dissect genotype-phenotype relationships.

Primary microcephaly arises from disruptions in pathways controlling neural progenitor cell (NPC) proliferation and differentiation. Key pathways include:

1. Centrosome and Spindle Pole Assembly: Mutations in centrosomal proteins (e.g., ASPM, WDR62, CDK5RAP2) impair mitotic spindle orientation, leading to asymmetric cell division and premature differentiation of NPCs.

2. DNA Damage Response: Defects in genes like MCPH1 (microcephalin) disrupt the DNA damage checkpoint, causing cell cycle arrest and apoptosis in NPCs.

3. Wnt Signaling: Aberrant Wnt/beta-catenin signaling affects NPC self-renewal and cortical neurogenesis.

4. Ciliary Signaling: Mutations in CENPJ and other centriolar proteins impair primary cilia function, disrupting Sonic hedgehog (Shh) signaling and neurogenesis.

Data from NCBI Gene (2024), ClinVar (2024), and COSMIC (v101).

Key signaling networks disrupted in MCPH include:

• • Centrosome Signaling: ASPM, WDR62, CDK5RAP2, CENPJ, STIL, and MCPH1 are core components. Loss leads to mitotic spindle misorientation and premature differentiation.
• • DNA Damage Response: MCPH1 and BRCA1 interact to regulate the G2/M checkpoint. Loss of MCPH1 causes chromosomal instability.
• • Wnt/beta-catenin Pathway: ASPM and WDR62 modulate beta-catenin activity; dysregulation reduces NPC self-renewal.
• • Shh Signaling: CENPJ and other centriolar proteins are required for primary cilia formation, which transduces Shh signals essential for cortical expansion.

Organoids derived from patient iPSCs provide a 3D model of cortical neurogenesis, allowing study of NPC proliferation and differentiation in a more physiologically relevant context.

• • Aspm knockout mouse: Recapitulates microcephaly, reduced cortical surface area, and impaired neurogenesis.
• • Wdr62 mutant mouse: Shows reduced brain size and mitotic defects in NPCs.
• • Cdk5rap2 knockout mouse: Displays severe microcephaly and centrosome abnormalities.
• • Zebrafish models: Used for high-throughput drug screening due to rapid development and transparency.
• • Patient-derived xenografts (PDX): Limited in MCPH due to lack of tumorigenicity; primarily used for cancer-related microcephaly models.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise MCPH mutations. Examples include:

• • ASPM knockout in SH-SY5Y or HEK293T cells: Recapitulates centrosome defects and reduced proliferation.
• • WDR62 knock-in with patient-specific missense mutations: Allows study of dominant-negative effects.
• • CDK5RAP2 knockout in iPSC-derived NPCs: Models centrosome maturation failure.
• • CENPJ knockout in retinal pigment epithelial (RPE1) cells: Used for ciliary function assays.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent, validated models. These isogenic lines enable direct comparison between mutant and wild-type cells, reducing variability and improving reproducibility.

Gene-edited cell models are essential for validating the functional impact of MCPH mutations. For example:

• • ASPM knockout in SH-SY5Y cells demonstrates reduced cell proliferation and increased apoptosis, confirming its role in neurogenesis.
• • WDR62 knockout in iPSC-derived NPCs shows mitotic spindle misorientation and premature differentiation, linking genotype to phenotype.
• • CDK5RAP2 knockout in HEK293T cells reveals impaired centrosome maturation, providing mechanistic insight.

Isogenic cell pairs (wild-type vs. MCPH mutant) are used for high-throughput drug screening to identify compounds that rescue proliferation or reduce apoptosis. For example:

• • Screening for small molecules that enhance ASPM expression or function in ASPM knockout cells.
• • Testing compounds that stabilize centrosome structure in WDR62 mutant cells.
• • Evaluating drugs that modulate the DNA damage response in MCPH1-deficient cells.

These models also help study resistance to therapies that target cell cycle or centrosome function.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, selectively kill MCPH mutant cells. For example:

• • In ASPM-deficient cells, screening for synthetic lethal partners may reveal vulnerabilities that can be targeted therapeutically.
• • In WDR62 mutant NPCs, identifying genes that compensate for mitotic defects could lead to new drug targets.
• • Proteomic and transcriptomic analysis of isogenic lines can identify secreted biomarkers for disease monitoring.